Mineralys Eyes FDA Finish Line with Dual-Action Lorundrostat Data

RADNOR, Pa. – October 22, 2026 — The intersection of chronic kidney disease (CKD) and treatment-resistant hypertension has long been a clinical minefield, fraught with therapies that either fail to reach blood pressure targets or trigger dangerous electrolyte imbalances. But new Phase 3 data presented today at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver suggests that a novel class of targeted therapies may finally bridge this gap, offering significant implications for both patient outcomes and the biopharmaceutical market.

Mineralys Therapeutics, a clinical-stage biopharmaceutical company focused on aldosterone-driven diseases, unveiled compelling results from its pivotal Launch-HTN trial. The data demonstrated that lorundrostat, the company’s highly selective aldosterone synthase inhibitor, achieved statistically significant and clinically meaningful blood pressure reductions in patients with and without CKD. Crucially, it also halved albuminuria—a key marker of kidney damage—in the CKD cohort, cementing the drug’s potential as a dual-action cardiorenal therapy.

As Mineralys approaches a critical Food and Drug Administration (FDA) Prescription Drug User Fee Act (PDUFA) target action date of December 22, 2026, the institutional focus is intensifying. The results not only validate the scientific premise of targeting aldosterone synthesis but also position the company to capture a substantial share of a massive, historically underserved market.

Redefining Treatment for Resistant Hypertension in CKD

For the estimated 37 million adults in the United States living with CKD, managing hypertension is a high-stakes endeavor. Up to 75% of these patients suffer from uncontrolled high blood pressure, significantly elevating their risk of cardiovascular mortality and progression to end-stage renal disease.

The Launch-HTN trial, a global, randomized, double-blind, placebo-controlled study, enrolled adults whose blood pressure remained uncontrolled despite regimens of two to five standard antihypertensive medications. The results presented by Dr. Liffert Vogt, Professor of Clinical Nephrology and Renal Physiology at Amsterdam University Medical Center, showcased stark improvements.

At week 12, lorundrostat reduced placebo-adjusted systolic blood pressure (SBP) by 9.6 mmHg in participants with CKD (p=0.0022) and by 12.2 mmHg in those without the disease (p<0.0001). Furthermore, nearly half of the participants reached the stringent target SBP of below 130 mmHg: 44% in the CKD group (versus 18% on placebo) and 48% in the non-CKD group (versus 22% on placebo).

Beyond blood pressure, the trial delivered a critical secondary victory for renal health. Among CKD participants with baseline albuminuria, lorundrostat reduced the urine albumin-to-creatinine ratio (UACR) by 52.2% compared to placebo.

"These results are encouraging. Besides impacting blood pressure in participants with and without kidney disease, treatment with lorundrostat showed a meaningful reduction in albuminuria, a key marker for cardiovascular and kidney risk control," said Dr. Vogt during the presentation. "In patients with chronic kidney disease, high blood pressure and albuminuria are two of the most important risk factors we can modify, and lorundrostat improved both in this trial."

The Safety Equation: Navigating Hyperkalemia Risks

The Achilles heel of existing aldosterone-targeting therapies—namely mineralocorticoid receptor antagonists (MRAs) like spironolactone and finerenone—has historically been hyperkalemia, or dangerously high potassium levels. In patients with compromised kidney function, this risk is magnified, often leading to treatment discontinuation.

Clinical benchmarks underscore the severity of this issue. Trials for finerenone have shown treatment-emergent hyperkalemia rates exceeding 21%, while older steroidal MRAs like spironolactone can trigger hyperkalemia in over 60% of patients in certain high-risk cohorts.

By contrast, lorundrostat targets the hormonal cascade further upstream. As an investigational, orally administered inhibitor, it selectively blocks CYP11B2, the enzyme responsible for aldosterone production, while sparing the closely related cortisol-synthase pathway (CYP11B1). This highly targeted mechanism appears to pay dividends in safety. In the Launch-HTN trial, confirmed hyperkalemia occurred in just 2.4% of CKD participants and 0% of non-CKD participants—a remarkably low incidence that could shift the standard of care in nephrology clinics.

"CKD affects approximately 37 million adults in the U.S., and up to 75% of patients with CKD have uncontrolled hypertension. Aldosterone is a common driver of both hypertension and CKD, and lorundrostat is designed to reduce aldosterone at the source," stated Dr. Terry Ferguson, Chief Medical Officer of Mineralys Therapeutics. "In Launch-HTN, lorundrostat provided similar blood pressure reductions in participants with or without CKD, and it not only did so across a broad spectrum of the disease, but it did it in a way that reduced albuminuria."

The Race to Market: Aldosterone Synthase Class Gains Ground

From an institutional perspective, the ASN Kidney Week presentation is a vital de-risking event for Mineralys Therapeutics. With a market capitalization hovering around $2.26 billion, the company's valuation is intrinsically tied to lorundrostat, its sole late-stage asset.

The commercial stakes are exceptionally high. Approximately 15 to 20 million patients in the U.S. have resistant hypertension, and dysregulated aldosterone is believed to be the primary driver in about 30% of these cases. If approved, lorundrostat will enter a fiercely competitive landscape, racing against other emerging aldosterone synthase inhibitors like AstraZeneca’s baxdrostat.

However, Mineralys has aggressively maneuvered to secure its commercial footing. In June 2026, the company executed a strategic $200 million cash buyout to eliminate future royalty payments to Mitsubishi Tanabe Pharma Corporation, from whom lorundrostat was originally licensed. To fund this transaction and bolster its launch runway, Mineralys secured a senior secured term loan facility of up to $500 million.

Financial analysts note that this aggressive capital restructuring—trading upfront cash for royalty-free, perpetual intellectual property rights—signals immense internal confidence in the FDA approval process. The subsequent appointment of Dr. Ferguson as Chief Medical Officer in August further telegraphs the company’s pivot from clinical development to commercial execution.

Closing the Gap for Millions Left Behind

The implications of the Launch-HTN data extend far beyond the trading floor. Hypertension remains a leading cause of death in the United States, contributing to over 685,000 fatalities in 2022 alone and creating an estimated annual economic burden of $219 billion.

For the millions of patients taking up to five daily medications without relief, the advent of highly selective aldosterone synthase inhibitors represents a paradigm shift. Traditional therapies often fail to address the root endocrine drivers of the disease. By suppressing aldosterone at its source, lorundrostat not only mitigates vascular inflammation and sodium retention but also shields the kidneys from progressive fibrosis.

As the December 22 PDUFA date looms, the medical and investment communities are watching closely. The data presented in Denver provides a robust clinical narrative: a therapy that delivers dual cardiorenal protection without the severe electrolyte liabilities of its predecessors. Should the FDA grant approval, lorundrostat may rapidly transition from a late-stage clinical prospect to a foundational therapy, offering a new frontier of hope for patients caught in the dangerous overlap of kidney disease and resistant hypertension.